iCAD Gains CFDA Approval to Market Brachytherapy Device in China
publication date: Aug 31, 2017
iCAD, a New Hampshire medical device maker, announced CFDA approval of its Xoft Axxent balloon applicators, which are used in Brachytherapy treatment of breast cancer. The devices allow a small radiation source to be placed in the cavity created during a lumpectomy. The low dose radiation affects tissue close to the source, while minimizing harm to more distant tissue. The CFDA approval allows iCAD to market its complete Xoft® Axxent® Electronic Brachytherapy (eBx®) System® as an intraoperative treatment in China for women with early-stage breast cancer. More details....
Stock Symbol: (NSDQ: ICAD)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.